The Review on current treatments and therapies on COVID-19
Formulation Development of Sustained Release Matrix Tablet
Coronavirus are enveloped RNA Virus related to family ‘Coronaviride’. In December 2019, many pneumonia cases reported by patients with unknown causes mainly associated with seafood and wet market in when China and they are clinically resembled with viral pneumonia at present time there is no antiviral drug for the treatment of COV infection but some drugs and therapies gives effective action in the treatment and prevention of the SAR-COV-1 and MERS COV and these particular drugs and therapies plays important role in prevention and cure of SARS-COV-2 (COVID-19) such as Hydroxy-chloroquine and Chloroquine, Remdesivir, Ivermectin, Lopinavir/Ritonavir, Favipiravir and therapies may include convalescent plasma therapy and corticosteroids.Hydroxyl-chloroquine and chloroquine exibites its action against SARS-COV-2 by blocking the entry of viral cell inhibiting glycosylation of host receptor Ivermectin show anti SARS-COV-2 action by binding of Ivermectin to the imp α/β1 binding to viral proteins. This particular action prevents the viral from entering the nucleus which leads to reducing inhibition and antiviral response. Remdisivir (G-S5734) is an RdRP polymerase inhibitor and exhibites anti SARS-COV-2 action by inhibiting viral nucleic acid synthesis. Patients treated with convalscent plasma therapy and corticosteroids gives less mortality rate and has no adverse effect .The speed and volume of clinical preliminaries propelled research expected treatments for COVID-19 feature both the need and capacity to treat excellent proof even in pandemic no treatment demonstrate effective to date.
2. Fehr,A.R, Perlman, S.2015 corona virus ad overview of their replication and pathogenesis corona virus; methods and protocols,pages1-23.
3. Hui,D.S, Azhar, e, Madam T.A Ntoumi, F. Kock, R, Dar, Peterson, E.2020. The conting 2019-n COV epwdwmic threat of novel coronavirus outbreak in Wuhan China, International Jouranal of Infectious Diseases, 91:264-266.
4. Hussain A. Rothan, Siddappa N. Byrareddy. The epidemiology and pathogenesis of corona virus disease (COVId-19) Outbreak, (Feb 26) 2020.https://doi.org/10.1016/j.jaut.2020.102433
5. Tanya Lewis, Here’s what we know about the most jouted Drugs tesed for COVId-19, scientific American 175, (April 16)2020,https://www.scientificamerican.com/article/heres-what-we-know-about-the-most-touted-drugs-tested-for-covid-191/
6. Al-Bari MAA, Targetingendosomal acidification analogues as a promising strategy for the treatment of emerging viral diseases, pharmacol Res perspect,2017;5:e00293.
7. Zhou D, Dai SM, Tong Q COVID-19; a recommendation to examine the effect hydroxyl chloroquine in preventing infection and progression.[Published online march 20,2020],https://doi.org/10.1093/jac/dkaa114
8. Devaux. CA, Rolain JM, Colson P, Rault D. New insignts on antiviral effects of chloroquine against coronavirus: What do except for COVID-19? Int J Anti Microbe Agents published online March 4,2020,https://www.sciencedirect.com/science/article/pii/s0924857920300881
9. Colson p, Rolain JM, Lagier JC, Brouqui p, Rault D. Chloroquine as available weapons to fight COVId-19. Int J Anti microbial Agnts. Publishing online March 4,2020.doi:10.1016/j.ijantimicag.2020.105932
10. Yao X, Ye F, zhang m, etal In vitro Antiviral activity and pro9jection of optimized dosing design of hydroxychloroquine for treatment of severe acute respiratory syndrome coronavirus 2 ( SARS-COV-2) Clin infect Dis, published online march 9,2020.doi:10.1093/cid/ciaa237
11. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA approved drug Ivermectin inhibits the Replication of SARS COv-2 In-Vitro Antiviral Res.2020.https://doi.org/10.1016/j.antiviral.2020.104787.
12. Campbell WC, Benz GW, Ivermectin a review Of efficiency and safely Jvet parmacol ther.1984; 7(1):1-16.
13. Sharun K, Shyam Kumar T.S, Anne shava Dhama K, pawed AM, Pal A, current therapeutic application and pharmaco kinetic modulation of Ivermectin vet world 2019; 12(8):1204-11.https://doi.org/10.14202/vetworld.2019.1204.-1211.
14. Nguyen kY, Sakuna K, Kinobe R, Owens L, Ivermectin blocks the parvovirus in crayfish, cherax,quadric carinatus aquaculture 2014;420-421:288-94.https://doi.org/10.1016/j.aquaculture.2013.11.022.
15. Barrows NJ, COmpas Rk Powell ST, Prasanth Kr, Schoott- Lerner G, Soto-Acossta R, Galarza-Munoz G, MC Grath EL, Urraboz-Garza R, Gao J, Wap, Menon R, Saade G, Fernandez salas, Rossp SL, Vasilak is N, Routh A, Bradrick SS, Garcia- Blanco MA . A screen of FDA- approved drugs for inhibitors of ZIka virus infection cell host Microbe.2016; 20(2):259-70.https://doi.org/10.1016/j.chom.2016.07.004.
16. 16)Dwight L, Mckee, Ariane Sternberg, Ulrike stange Stefan Lanfer, cord Nau jokat candidate drugs against SARS-COV-2 and COVID-19 (March 27) (2020),https://doi.org/10.1016/j.phrs.2020.14859
17. E.P Tche snokov, J.Y Feng, D.P Porter M. Gotte, mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdisivir, Viruses 11(4) (2019) 326.
18. Yu-CHem Cao, Qi-Xin Deng shi-xue Dia, REmdisivir for several acute respiratory syndrome coronavirus-2 causing COVID-19: An evaluation of evidence, (March) (2020),https://doi.org/10.1016/j.tmaid.2020.101647
19. Wang M, CaoR, Zhang l, etal. Remdisivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV-) in vitro.cell Res.2020; 30(3):269-271.doi:10.1038/s41422-020-0282-0.
20. Li, G, De clearcq, E.2020. Therapeutic options for the 2019 novel coronavirus (2019-n COV) Nat Rev Drug Discov 2020; 19:149-50. https//doi.org/10.1038/d41573-020-00016-0.
21. Chu, C.M. Cheng, VCC, Hung, IFN.Wong MML,Chan KH,Chan KS,et al. Role of Lopinavir/ Ritonavir in the treatment of SARS; initial viriologycal and clinical findings thorax59. Thorax 2004; 59:252-6.
22. Chan J.F, Yao, Y.Yeung, ML, etal, Treatment with Lpinavir / Ritonavir or Interferor-β1b improve outcone of MERS-COV infection in a non human primate model of common marmoset, J Infect Dis, 2015; 212:1904-13.
23. Yao, T.T,Qian, JD, zhu W.Y Wang, Y, Wang Gq,2020 A Systematic review of Lopinavir therapy for SARS coronavirus and MERS corona virus-A possible refrence for coronavirus disease-19 treatment option J. Med virol,https://doi.org/10.1002/jmv.25729
24. Nutho B mahalapbutr, P. Hengpha satporn,K.etal 2020. Ehy are lopinavir and ritonav9ir effective against the nearky emerged 2019? Atomistic insights into the inhibitory mechanisms, Biochemistry 59, 1769-1779,https://puhs.acs.org/doi/abs/10.1021/acs.biochem.0c00160#
25. Sanders, J.M. Monogue ML, Jodlo0wski T.Z, Cutrell, JB, 2020. Pharmacologic treatment for coronavirus disease 2019 (COVID-19): a review. JAMA,https://jamanetwork.com/journals/jama/fullarticle/2764727/
26. Cao, B. Wng Y, WEn D, etal, 2020. A trial of lopinavir- ritonavir in adults hospitalzedwith severe COVID-19. NEngl J Med 2020; 382:1787-99.
27. Eric A Coomes and Hourmazd Haghbhayan. Favipiravir, an antiviral for COVID-19. 2020 May 17.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239147/
28. Favipiravir, Wikipedia , mechanism of Favipiravir.wikipedia.com
29. Cheng Y, Wong R, Sooyo, wtal, use of convalescent plasma therapy in SARS. Patients in hong kong Eur J Clin Microbial Infect Dis 2005; 24:44-46.
30. Who use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for Transfusin as an empirical treatment during outbreak 2014.https://apps.who.int/iris/rest/bitstreams/604045/retrieve (accessed Feb 20,2020)
31. Arabi Y, Balkhy H, Hajeer AH, feasibility safety, clinical and laboratory effects of convalescent plasma therapy for patients with middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus 2015; 4:709.
32. Mair-Jerkins J, Saaavedra-campos M , Baillaie JK etal. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral Etiology: asystematic review and exploratory Meta-analysis. J Infect Dis 2015;211;80-90
33. Luke TC, Kilbane EM Jackson JL Hoffman SL. Meta- analysis: convalescent blood products for Spanish influenza pneumonia a future H5N1 treatment? Ann Intern med 2006; 145:599-609.
34. Schoofs T, Klein F, Braun Scheveig M etal- HIV-1 therapy with monocolonal responses against Hiv-1 Science 2016; 352:997-1001.
35. Z.G.Zhou, S-M Xie, J. Zhang,F. Zheng, D.X.Jiang, K.Y. Li eatal ,short term moderate- dose corticosteroid plus immunoglobulin effectively reverse COVID-19 Patients who have failed low-dose therapy 2020,https://www.researchsquare.com/article/rs-34078/v1
36. X,Xu,M.Han, T.Li, W. Sun, D.Wang, B.fu, etal, effective treatment of severe COVID-19 patients with Tocilizumab, China Xiv 2020;202003:v1.
37. C. Bergin, N. Conlon, C.N. Choitir, R. Admas, F.king, P.Gilvarry, Interim recommensations for the use of Tocilizumab in management of patients who have severe COVID-19 with suspected Hyperinflammation,2020.
38. C.D. Russsel, j.E millar,J.K.Baillie, Clinica evidence does not support corticosteroid treatment for 2019-nCOV lung injury, The Lancet. 395(10223) (2020)
39. S. Matsuyama, M. Kawase, N.NAo, Shirato, m.Ujike, W. Kamitani, etal, The inhaled corticosteroid ciclesonide blocks coronaivrus RNA replication by targeting viral NSP15, bio Rxiv 2020.https://www.doi.org/10.1101/2020.3.11.987016
40. Y.Wang, W.Jiang, Q.He, C,Wang, B. Wang p. Zhou, etal, Early, low dose and short term application of corticosteroid treatment ion patients with severe COVID-19 pneumonia:single-centre experience from Wuhan, China, med Rxiv 2020.https://doi.org/10.1101/202.03.06.20032342
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).